S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NASDAQ:OPGN

OpGen Stock Forecast, Price & News

$3.05
-0.06 (-1.93 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.01
$3.12
50-Day Range
$2.20
$3.58
52-Week Range
$1.63
$4.37
Volume581,695 shs
Average Volume4.72 million shs
Market Capitalization$116.72 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.56
30 days | 90 days | 365 days | Advanced Chart
Receive OPGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.


OpGen logo

About OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It also engages in the development of molecular information products and services for global healthcare settings. It also offers guidance to clinicians about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The firms products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.04 out of 5 stars

Medical Sector

512th out of 1,351 stocks

Medical Laboratories Industry

14th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











OpGen (NASDAQ:OPGN) Frequently Asked Questions

Is OpGen a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OpGen stock.
View analyst ratings for OpGen
or view top-rated stocks.

What stocks does MarketBeat like better than OpGen?

Wall Street analysts have given OpGen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but OpGen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting OpGen?

OpGen saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 777,900 shares, an increase of 50.6% from the August 15th total of 516,400 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is presently 0.6 days. Currently, 2.0% of the shares of the stock are short sold.
View OpGen's Short Interest
.

When is OpGen's next earnings date?

OpGen is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for OpGen
.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) issued its earnings results on Thursday, August, 12th. The medical research company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. OpGen had a negative trailing twelve-month return on equity of 99.01% and a negative net margin of 906.54%.
View OpGen's earnings history
.

How has OpGen's stock price been impacted by COVID-19?

OpGen's stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPGN shares have increased by 47.3% and is now trading at $3.05.
View which stocks have been most impacted by COVID-19
.

When did OpGen's stock split? How did OpGen's stock split work?

OpGen shares reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for OPGN?

2 brokerages have issued 12-month target prices for OpGen's stock. Their forecasts range from $4.00 to $7.00. On average, they anticipate OpGen's share price to reach $5.50 in the next year. This suggests a possible upside of 80.3% from the stock's current price.
View analysts' price targets for OpGen
or view top-rated stocks among Wall Street analysts.

Who are OpGen's key executives?

OpGen's management team includes the following people:
  • Oliver Schacht, Chief Executive Officer & Director
  • Johannes Bacher, Chief Operating Officer
  • Vadim Sapiro, Chief Information Officer
  • Faranak Atrzadeh, Chief Marketing & Scientific Affairs Officer
  • Al Risdorfer, Senior Director-Human Resources

What other stocks do shareholders of OpGen own?

When did OpGen IPO?

(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Who are OpGen's major shareholders?

OpGen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.61%), Geode Capital Management LLC (0.84%), State Street Corp (0.26%), Renaissance Technologies LLC (0.23%), Northern Trust Corp (0.19%) and Susquehanna Fundamental Investments LLC (0.13%). Company insiders that own OpGen stock include Evan/ Fa Jones, Johannes Bacher, NV In Liquidation Curetis and Oliver Schacht.
View institutional ownership trends for OpGen
.

Which major investors are selling OpGen stock?

OPGN stock was sold by a variety of institutional investors in the last quarter, including National Asset Management Inc., Citadel Advisors LLC, Schonfeld Strategic Advisors LLC, Virtu Financial LLC, and XTX Topco Ltd.
View insider buying and selling activity for OpGen
or view top insider-selling stocks.

Which major investors are buying OpGen stock?

OPGN stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, State Street Corp, Vanguard Group Inc., Renaissance Technologies LLC, Susquehanna Fundamental Investments LLC, Millennium Management LLC, Northern Trust Corp, and Charles Schwab Investment Management Inc.. Company insiders that have bought OpGen stock in the last two years include Johannes Bacher, and Oliver Schacht.
View insider buying and selling activity for OpGen
or or view top insider-buying stocks.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $3.05.

How much money does OpGen make?

OpGen has a market capitalization of $116.72 million and generates $4.21 million in revenue each year. The medical research company earns $-26,210,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does OpGen have?

OpGen employs 102 workers across the globe.

What is OpGen's official website?

The official website for OpGen is www.opgen.com.

Where are OpGen's headquarters?

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at (240) 813-1260 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.